The incidence of pancreatic neuroendocrine tumor (PNET) is increasing, and it presents with
various clinical manifestations and an unfavorable survival rate. A better understanding of …

KRAS activation occurring in more than 90% of pancreatic ductal adenocarcinomas (PDAC)
drives progression and metastasis, but the underlying mechanisms involved in these …

Background MicroRNAs (miRNAs) can act as oncogenes or tumor suppressors by
controlling cell proliferation, differentiation, metastasis and apoptosis, and miRNA …

Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive neoplasm, predicted
to become the second leading cause of cancer-related deaths before 2030. This dismal …

Outcomes for patients with pancreatic cancer (PC) are poor; therefore, there is an urgent
need to identify novel therapeutic targets involved in the progression of PC. We previously …

Metastasis remains one of the most intractable challenges in pancreatic ductal
adenocarcinoma (PDAC) biology, and epithelial-to-mesenchymal transition (EMT) is …

Pancreatic neuroendocrine tumours (PNETs) are relatively uncommon, accounting for 1–2%
of all pancreatic neoplasms. Tumour grade (based on the Ki67 proliferative index and mitotic …

Invasive ductal adenocarcinoma (IDA) of the pancreas manifests poor prognosis due to the
early invasion and distant metastasis. In contrast, intraductal papillary mucinous adenoma or …

Background: Pancreatic ductal adenocarcinoma (PDAC) is the 4th leading cause of cancer
deaths in the US due to the lack of effective targeted therapeutics and extremely poor …

Background miRNAs are involved in coordinating a variety of cellular processes by
regulating their target genes. Aberrant expression of miRNAs is correlated with various …